BACKGROUND: IL-13 is a central mediator of airway responsiveness and mucus expression in patients with allergic airway inflammation, and IL-13 is currently a therapeutic target for asthma. However, little is known about how IL-13 regulates human CD4(+) T-cell lineages because IL-13 receptor (IL-13R) α1, a subunit of IL-13R, has not previously been reported to exist on human T cells. OBJECTIVE: We sought to determine whether human CD4(+) T(H)17 cells express IL-13Rα1 and whether IL-13 regulates T(H)17 cytokine production. METHODS: Naive human CD4(+) cells were isolated from whole blood, activated with anti-CD3 and anti-CD28, and polarized to T(H)1, T(H)2, T(H)17, or induced regulatory T cells in the presence of IL-13 (0-10 ng/mL). Cell supernatants, total RNA, or total protein was examined 4 days after T(H)17 polarization. RESULTS: T(H)17 cells, but not T(H)0, T(H)1, T(H)2, or induced regulatory T cells, expressed IL-13Rα1. IL-13 attenuated IL-17A production, as well as expression of retinoic acid-related orphan receptor, runt-related transcription factor-1, and interferon regulatory factor 4 in T(H)17-polarized cells. IL-13 neither inhibited IFN-γ production from T(H)1 cells nor inhibited IL-4 production from T(H)2 cells. Furthermore, attenuation of IL-17A production only occurred when IL-13 was present within 24 hours of T-cell activation or at the time of restimulation. CONCLUSIONS: IL-13Rα1 is expressed on human CD4(+) T(H)17 cells, and IL-13 attenuates IL-17A production at polarization and restimulation. Although IL-13 is an attractive therapeutic target for decreasing symptoms associated with asthma, these results suggest that therapies inhibiting IL-13 production could have adverse side effects by increasing IL-17A production.
BACKGROUND: IL-13 is a central mediator of airway responsiveness and mucus expression in patients with allergic airway inflammation, and IL-13 is currently a therapeutic target for asthma. However, little is known about how IL-13 regulates human CD4(+) T-cell lineages because IL-13 receptor (IL-13R) α1, a subunit of IL-13R, has not previously been reported to exist on human T cells. OBJECTIVE: We sought to determine whether human CD4(+) T(H)17 cells express IL-13Rα1 and whether IL-13 regulates T(H)17 cytokine production. METHODS: Naive human CD4(+) cells were isolated from whole blood, activated with anti-CD3 and anti-CD28, and polarized to T(H)1, T(H)2, T(H)17, or induced regulatory T cells in the presence of IL-13 (0-10 ng/mL). Cell supernatants, total RNA, or total protein was examined 4 days after T(H)17 polarization. RESULTS: T(H)17 cells, but not T(H)0, T(H)1, T(H)2, or induced regulatory T cells, expressed IL-13Rα1. IL-13 attenuated IL-17A production, as well as expression of retinoic acid-related orphan receptor, runt-related transcription factor-1, and interferon regulatory factor 4 in T(H)17-polarized cells. IL-13 neither inhibited IFN-γ production from T(H)1 cells nor inhibited IL-4 production from T(H)2 cells. Furthermore, attenuation of IL-17A production only occurred when IL-13 was present within 24 hours of T-cell activation or at the time of restimulation. CONCLUSIONS: IL-13Rα1 is expressed on human CD4(+) T(H)17 cells, and IL-13 attenuates IL-17A production at polarization and restimulation. Although IL-13 is an attractive therapeutic target for decreasing symptoms associated with asthma, these results suggest that therapies inhibiting IL-13 production could have adverse side effects by increasing IL-17A production.
Authors: Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo Journal: Nature Date: 2006-04-30 Impact factor: 49.962
Authors: Gaoyun Yang; Amy Volk; Ted Petley; Eva Emmell; Jill Giles-Komar; Xiaozhou Shang; Jian Li; Anuk M Das; Dave Shealy; Don E Griswold; Li Li Journal: Cytokine Date: 2004-12-21 Impact factor: 3.861
Authors: Ilkka S Junttila; Kiyoshi Mizukami; Harold Dickensheets; Martin Meier-Schellersheim; Hidehiro Yamane; Raymond P Donnelly; William E Paul Journal: J Exp Med Date: 2008-10-13 Impact factor: 14.307
Authors: Liang Zhou; Ivaylo I Ivanov; Rosanne Spolski; Roy Min; Kevin Shenderov; Takeshi Egawa; David E Levy; Warren J Leonard; Dan R Littman Journal: Nat Immunol Date: 2007-06-20 Impact factor: 25.606
Authors: Britta C Martel; Beatrice Dyring-Andersen; Lone Skov; Kristian Thestrup-Pedersen; Søren Skov; Kresten Skak; Lars K Poulsen Journal: Inflamm Res Date: 2015-12-31 Impact factor: 4.575
Authors: Vahe Badalyan; Robert Thompson; Kezia Addo; Lee A Borthwick; Andrew J Fisher; Tatiana Ort; Timothy G Myers; Thomas A Wynn; Thirumalai R Ramalingam Journal: J Allergy Clin Immunol Date: 2014-06-20 Impact factor: 10.793
Authors: Daniel E Dulek; Dawn C Newcomb; Kasia Goleniewska; Jaqueline Cephus; Weisong Zhou; Sara Reiss; Shinji Toki; Fei Ye; Rinat Zaynagetdinov; Taylor P Sherrill; Timothy S Blackwell; Martin L Moore; Kelli L Boyd; Jay K Kolls; R Stokes Peebles Journal: Infect Immun Date: 2014-06-23 Impact factor: 3.441
Authors: Min Xie; Anthony T Mustovich; Yi Jiang; John B Trudeau; Anuradha Ray; Prabir Ray; Haizhen Hu; Fernando Holguin; Bruce Freeman; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2014-10-11 Impact factor: 10.793
Authors: Sara L Hall; Theresa Baker; Stephane Lajoie; Phoebe K Richgels; Yanfen Yang; Jaclyn W McAlees; Adelaide van Lier; Marsha Wills-Karp; Umasundari Sivaprasad; Thomas H Acciani; Timothy D LeCras; Jocelyn Biagini Myers; Melinda Butsch Kovacic; Ian P Lewkowich Journal: J Allergy Clin Immunol Date: 2016-06-11 Impact factor: 10.793
Authors: Dirkjan Hijnen; Edward F Knol; Yoony Y Gent; Barbara Giovannone; Scott J P Beijn; Thomas S Kupper; Carla A F M Bruijnzeel-Koomen; Rachael A Clark Journal: J Invest Dermatol Date: 2012-12-06 Impact factor: 8.551